ArticleFrontiers in allergy2026
Exploring associations between nasal fluid inflammatory proteins and patient-reported symptom burden in respiratory disease.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patient-reported outcome measures are widely used to assess symptom burden in respiratory disease, yet the extent to which symptom severity reflects underlying mucosal biology remains incompletely understood. Nasal fluid provides a non-invasive matrix for assessing airway inflammation within the unified airway framework. Methods: In this exploratory study, nasal fluid samples were collected from 30 participants with heterogeneous respiratory conditions, and protein concentrations were measured using a multiplex immunoassay. Associations between protein concentrations and symptom burden, measured using the 22-item Sino-Nasal Outcome Test (SNOT-22), were assessed using Spearman correlations. Results: Protein concentrations of 40 analytes were measured and were found to span a wide dynamic range across participants. The mean SNOT-22 score was 39.1 (range, 3-89). TRAIL and CXCL10 demonstrated positive correlations with SNOT-22 scores (rho = 0.563, Discussion: These findings demonstrate the feasibility of linking non-invasive nasal fluid biomarkers with composite symptom scores in a heterogeneous respiratory cohort. Together, they support the potential of nasal fluid profiling to capture clinically relevant biological variation and inform larger, multimodal studies integrating complementary clinical and physiological measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.